$8.61 0.1%
ENGN Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About enGenes

enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.


enGenes
Price $8.61
Target Price Sign up
Volume 69,670
Market Cap $423M
Year Range $5.26 - $18.24
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2405.2M-5.2M-14M-13M-0.320
Q2 '2407.5M-8.2M-15M-14M-0.380
Q1 '2405.1M-6.1M-11M-10M-0.462
Q4 '23000-82M-81M-4.512
Q3 '23000-4.7M-8.8M-0.003

Insider Transactions View All

Forbion Growth Opportunities Fund I Cooperatief U.A. filed to buy 2,470,633 shares at $6.6.
October 18 '24
Forbion Growth Opportunities Fund I Cooperatief U.A. filed to buy 2,469,833 shares at $6.5.
October 18 '24
Forbion Growth Opportunities Fund I Cooperatief U.A. filed to buy 2,457,989 shares at $6.5.
October 18 '24
Forbion Growth Opportunities Fund I Cooperatief U.A. filed to buy 2,451,992 shares at $6.5.
October 18 '24
Forbion Growth Opportunities Fund I Cooperatief U.A. filed to buy 2,446,223 shares at $6.4.
October 18 '24

What is the Market Cap of enGenes?

The Market Cap of enGenes is $423M.

What is the current stock price of enGenes?

Currently, the price of one share of enGenes stock is $8.61.

How can I analyze the ENGN stock price chart for investment decisions?

The ENGN stock price chart above provides a comprehensive visual representation of enGenes' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling enGenes shares. Our platform offers an up-to-date ENGN stock price chart, along with technical data analysis and alternative data insights.

Does ENGN offer dividends to its shareholders?

As of our latest update, enGenes (ENGN) does not offer dividends to its shareholders. Investors interested in enGenes should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of enGenes?

Some of the similar stocks of enGenes are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.